Most Read Articles
Christina Lau, 13 Sep 2018

In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).

16 Apr 2016
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 07 Sep 2018

Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.

Pearl Toh, 20 Sep 2018
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.

PCSK9 inhibitors safe, effective for familial hypercholesterolaemia

10 Jan 2018

A meta-analysis of 1,526 patients showed that proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are safe and effective compared with placebo at reducing LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia (FH). [Singh A, et al, AHA 2017, abstract QCOR06]

Researchers from Brigham and Women’s Hospital in Boston, Massachusetts, US, included patients with FH from eight trials that compared PCSK9 inhibitors with standard therapy for at least 12 weeks of follow-up.

Treatment with PCSK9 inhibitors resulted in a mean 48.06 percent reduction in LDL-C compared with placebo.

Besides LDL-C, PCSK9 inhibitors were associated with the largest percent change in non–HDL-cholesterol, followed by apolipoprotein B, total cholesterol, lipoprotein (a), and triglycerides. HDL-cholesterol and Apolipoprotein A1 showed smaller percent increases.

“PCSK9 inhibitors were safe and well tolerated, with injection site reactions being the most common adverse effect,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Sep 2018

In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).

16 Apr 2016
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 07 Sep 2018

Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.

Pearl Toh, 20 Sep 2018
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.